Pascal's uncertainty principle: Managing drug–drug interactions when the risks are unclear

Therapeutic decision‐making (TDM) often occurs under conditions of scientific uncertainty, including decisions on how to manage the majority of drug–drug interactions (DDIs). The existence of many DDIs is not firmly established, and there is an unfortunate tendency to make decisions based on the bin...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:JAACP : Journal of the American College of Clinical Pharmacy 2024-12, Vol.7 (12), p.1197-1206
Hauptverfasser: Hansten, Philip D., Gomez‐Lumbreras, Ainhoa, Villa‐Zapata, Lorenzo, Malone, Daniel C.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 1206
container_issue 12
container_start_page 1197
container_title JAACP : Journal of the American College of Clinical Pharmacy
container_volume 7
creator Hansten, Philip D.
Gomez‐Lumbreras, Ainhoa
Villa‐Zapata, Lorenzo
Malone, Daniel C.
description Therapeutic decision‐making (TDM) often occurs under conditions of scientific uncertainty, including decisions on how to manage the majority of drug–drug interactions (DDIs). The existence of many DDIs is not firmly established, and there is an unfortunate tendency to make decisions based on the binary assessment of whether or not a particular DDI is real, rather than taking a more probabilistic and holistic approach to TDM. There also seems to be an undue fear of making a Type I error (assuming the DDI is real when it is not) while ignoring the often much greater risk of a Type II error (assuming the DDI is not real, when it is). Thus, a more rational TDM process for such DDIs is needed. In his famous “Wager,” philosopher‐mathematician Blaise Pascal made a probabilistic argument for believing in God. Instead of considering probability in isolation, Pascal linked the probability of God's existence with the severity of the outcome (an eternity in Hell for non‐believers) and also added a third factor—the ease with which the risk can be avoided. We propose a novel paradigm for TDM that uses all three of Pascal's steps: probability, severity, and avoidability. We present several specific DDI examples to demonstrate how Pascal's Uncertainty Principle can help pharmacists make clinical management decisions for these DDIs. We suggest that this process be called “Pascal's Uncertainty Principle” rather than “Pascal's Wager,” because it can be used to make rational decisions in the presence of uncertainty in many non‐theological situations. This process reinforces the value of philosophical training for pharmacy students.
doi_str_mv 10.1002/jac5.2031
format Article
fullrecord <record><control><sourceid>wiley_cross</sourceid><recordid>TN_cdi_crossref_primary_10_1002_jac5_2031</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>JAC52031</sourcerecordid><originalsourceid>FETCH-LOGICAL-c1591-384ca0d60baac048c2bc38591e824f7826b973e1eb72e2c1fdac54150f3ad8a33</originalsourceid><addsrcrecordid>eNp1kMFOwzAQRC0EElXpgT_wDXFIu7aTxuFWVVBARXCAG1K0cTatS3ArO1XVG__AH_IlJJQDF06z0r4ZaYaxcwFDASBHKzTJUIISR6wnkzSOMp3C8Z_7lA1CWAGAyFSsxbjHXp8wGKwvAt86Q75B65o933jrjN3UdMUf0OHCugUv_Xbx9fHZCW8h8mgau3aB75bkeLMk7m14Cxw9dVk1oT9jJxXWgQa_2mcvN9fP09to_ji7m07mkRFJJiKlY4NQjqFANBBrIwujdPshLeMq1XJcZKkiQUUqSRpRlW3PWCRQKSw1KtVnl4dc49cheKrytsA7-n0uIO-Wybtl8m6Zlh0d2J2taf8_mN9PpsmP4xuQ-Wb8</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Pascal's uncertainty principle: Managing drug–drug interactions when the risks are unclear</title><source>Wiley Online Library All Journals</source><creator>Hansten, Philip D. ; Gomez‐Lumbreras, Ainhoa ; Villa‐Zapata, Lorenzo ; Malone, Daniel C.</creator><creatorcontrib>Hansten, Philip D. ; Gomez‐Lumbreras, Ainhoa ; Villa‐Zapata, Lorenzo ; Malone, Daniel C.</creatorcontrib><description>Therapeutic decision‐making (TDM) often occurs under conditions of scientific uncertainty, including decisions on how to manage the majority of drug–drug interactions (DDIs). The existence of many DDIs is not firmly established, and there is an unfortunate tendency to make decisions based on the binary assessment of whether or not a particular DDI is real, rather than taking a more probabilistic and holistic approach to TDM. There also seems to be an undue fear of making a Type I error (assuming the DDI is real when it is not) while ignoring the often much greater risk of a Type II error (assuming the DDI is not real, when it is). Thus, a more rational TDM process for such DDIs is needed. In his famous “Wager,” philosopher‐mathematician Blaise Pascal made a probabilistic argument for believing in God. Instead of considering probability in isolation, Pascal linked the probability of God's existence with the severity of the outcome (an eternity in Hell for non‐believers) and also added a third factor—the ease with which the risk can be avoided. We propose a novel paradigm for TDM that uses all three of Pascal's steps: probability, severity, and avoidability. We present several specific DDI examples to demonstrate how Pascal's Uncertainty Principle can help pharmacists make clinical management decisions for these DDIs. We suggest that this process be called “Pascal's Uncertainty Principle” rather than “Pascal's Wager,” because it can be used to make rational decisions in the presence of uncertainty in many non‐theological situations. This process reinforces the value of philosophical training for pharmacy students.</description><identifier>ISSN: 2574-9870</identifier><identifier>EISSN: 2574-9870</identifier><identifier>DOI: 10.1002/jac5.2031</identifier><language>eng</language><publisher>Hoboken, USA: John Wiley &amp; Sons, Inc</publisher><subject>clinical decision‐making ; drug interactions ; oral contraceptives ; philosophy ; tamoxifen</subject><ispartof>JAACP : Journal of the American College of Clinical Pharmacy, 2024-12, Vol.7 (12), p.1197-1206</ispartof><rights>2024 The Author(s). JACCP: published by Wiley Periodicals LLC on behalf of Pharmacotherapy Publications, Inc.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c1591-384ca0d60baac048c2bc38591e824f7826b973e1eb72e2c1fdac54150f3ad8a33</cites><orcidid>0000-0002-5006-9394 ; 0000-0002-5835-7366 ; 0000-0002-3916-0402 ; 0000-0002-3821-4595</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2Fjac5.2031$$EPDF$$P50$$Gwiley$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Fjac5.2031$$EHTML$$P50$$Gwiley$$Hfree_for_read</linktohtml><link.rule.ids>314,780,784,1416,27922,27923,45572,45573</link.rule.ids></links><search><creatorcontrib>Hansten, Philip D.</creatorcontrib><creatorcontrib>Gomez‐Lumbreras, Ainhoa</creatorcontrib><creatorcontrib>Villa‐Zapata, Lorenzo</creatorcontrib><creatorcontrib>Malone, Daniel C.</creatorcontrib><title>Pascal's uncertainty principle: Managing drug–drug interactions when the risks are unclear</title><title>JAACP : Journal of the American College of Clinical Pharmacy</title><description>Therapeutic decision‐making (TDM) often occurs under conditions of scientific uncertainty, including decisions on how to manage the majority of drug–drug interactions (DDIs). The existence of many DDIs is not firmly established, and there is an unfortunate tendency to make decisions based on the binary assessment of whether or not a particular DDI is real, rather than taking a more probabilistic and holistic approach to TDM. There also seems to be an undue fear of making a Type I error (assuming the DDI is real when it is not) while ignoring the often much greater risk of a Type II error (assuming the DDI is not real, when it is). Thus, a more rational TDM process for such DDIs is needed. In his famous “Wager,” philosopher‐mathematician Blaise Pascal made a probabilistic argument for believing in God. Instead of considering probability in isolation, Pascal linked the probability of God's existence with the severity of the outcome (an eternity in Hell for non‐believers) and also added a third factor—the ease with which the risk can be avoided. We propose a novel paradigm for TDM that uses all three of Pascal's steps: probability, severity, and avoidability. We present several specific DDI examples to demonstrate how Pascal's Uncertainty Principle can help pharmacists make clinical management decisions for these DDIs. We suggest that this process be called “Pascal's Uncertainty Principle” rather than “Pascal's Wager,” because it can be used to make rational decisions in the presence of uncertainty in many non‐theological situations. This process reinforces the value of philosophical training for pharmacy students.</description><subject>clinical decision‐making</subject><subject>drug interactions</subject><subject>oral contraceptives</subject><subject>philosophy</subject><subject>tamoxifen</subject><issn>2574-9870</issn><issn>2574-9870</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid>24P</sourceid><sourceid>WIN</sourceid><recordid>eNp1kMFOwzAQRC0EElXpgT_wDXFIu7aTxuFWVVBARXCAG1K0cTatS3ArO1XVG__AH_IlJJQDF06z0r4ZaYaxcwFDASBHKzTJUIISR6wnkzSOMp3C8Z_7lA1CWAGAyFSsxbjHXp8wGKwvAt86Q75B65o933jrjN3UdMUf0OHCugUv_Xbx9fHZCW8h8mgau3aB75bkeLMk7m14Cxw9dVk1oT9jJxXWgQa_2mcvN9fP09to_ji7m07mkRFJJiKlY4NQjqFANBBrIwujdPshLeMq1XJcZKkiQUUqSRpRlW3PWCRQKSw1KtVnl4dc49cheKrytsA7-n0uIO-Wybtl8m6Zlh0d2J2taf8_mN9PpsmP4xuQ-Wb8</recordid><startdate>202412</startdate><enddate>202412</enddate><creator>Hansten, Philip D.</creator><creator>Gomez‐Lumbreras, Ainhoa</creator><creator>Villa‐Zapata, Lorenzo</creator><creator>Malone, Daniel C.</creator><general>John Wiley &amp; Sons, Inc</general><scope>24P</scope><scope>WIN</scope><scope>AAYXX</scope><scope>CITATION</scope><orcidid>https://orcid.org/0000-0002-5006-9394</orcidid><orcidid>https://orcid.org/0000-0002-5835-7366</orcidid><orcidid>https://orcid.org/0000-0002-3916-0402</orcidid><orcidid>https://orcid.org/0000-0002-3821-4595</orcidid></search><sort><creationdate>202412</creationdate><title>Pascal's uncertainty principle: Managing drug–drug interactions when the risks are unclear</title><author>Hansten, Philip D. ; Gomez‐Lumbreras, Ainhoa ; Villa‐Zapata, Lorenzo ; Malone, Daniel C.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c1591-384ca0d60baac048c2bc38591e824f7826b973e1eb72e2c1fdac54150f3ad8a33</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>clinical decision‐making</topic><topic>drug interactions</topic><topic>oral contraceptives</topic><topic>philosophy</topic><topic>tamoxifen</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Hansten, Philip D.</creatorcontrib><creatorcontrib>Gomez‐Lumbreras, Ainhoa</creatorcontrib><creatorcontrib>Villa‐Zapata, Lorenzo</creatorcontrib><creatorcontrib>Malone, Daniel C.</creatorcontrib><collection>Wiley-Blackwell Open Access Titles</collection><collection>Wiley Free Content</collection><collection>CrossRef</collection><jtitle>JAACP : Journal of the American College of Clinical Pharmacy</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Hansten, Philip D.</au><au>Gomez‐Lumbreras, Ainhoa</au><au>Villa‐Zapata, Lorenzo</au><au>Malone, Daniel C.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Pascal's uncertainty principle: Managing drug–drug interactions when the risks are unclear</atitle><jtitle>JAACP : Journal of the American College of Clinical Pharmacy</jtitle><date>2024-12</date><risdate>2024</risdate><volume>7</volume><issue>12</issue><spage>1197</spage><epage>1206</epage><pages>1197-1206</pages><issn>2574-9870</issn><eissn>2574-9870</eissn><abstract>Therapeutic decision‐making (TDM) often occurs under conditions of scientific uncertainty, including decisions on how to manage the majority of drug–drug interactions (DDIs). The existence of many DDIs is not firmly established, and there is an unfortunate tendency to make decisions based on the binary assessment of whether or not a particular DDI is real, rather than taking a more probabilistic and holistic approach to TDM. There also seems to be an undue fear of making a Type I error (assuming the DDI is real when it is not) while ignoring the often much greater risk of a Type II error (assuming the DDI is not real, when it is). Thus, a more rational TDM process for such DDIs is needed. In his famous “Wager,” philosopher‐mathematician Blaise Pascal made a probabilistic argument for believing in God. Instead of considering probability in isolation, Pascal linked the probability of God's existence with the severity of the outcome (an eternity in Hell for non‐believers) and also added a third factor—the ease with which the risk can be avoided. We propose a novel paradigm for TDM that uses all three of Pascal's steps: probability, severity, and avoidability. We present several specific DDI examples to demonstrate how Pascal's Uncertainty Principle can help pharmacists make clinical management decisions for these DDIs. We suggest that this process be called “Pascal's Uncertainty Principle” rather than “Pascal's Wager,” because it can be used to make rational decisions in the presence of uncertainty in many non‐theological situations. This process reinforces the value of philosophical training for pharmacy students.</abstract><cop>Hoboken, USA</cop><pub>John Wiley &amp; Sons, Inc</pub><doi>10.1002/jac5.2031</doi><tpages>10</tpages><orcidid>https://orcid.org/0000-0002-5006-9394</orcidid><orcidid>https://orcid.org/0000-0002-5835-7366</orcidid><orcidid>https://orcid.org/0000-0002-3916-0402</orcidid><orcidid>https://orcid.org/0000-0002-3821-4595</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 2574-9870
ispartof JAACP : Journal of the American College of Clinical Pharmacy, 2024-12, Vol.7 (12), p.1197-1206
issn 2574-9870
2574-9870
language eng
recordid cdi_crossref_primary_10_1002_jac5_2031
source Wiley Online Library All Journals
subjects clinical decision‐making
drug interactions
oral contraceptives
philosophy
tamoxifen
title Pascal's uncertainty principle: Managing drug–drug interactions when the risks are unclear
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-09T13%3A38%3A00IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-wiley_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Pascal's%20uncertainty%20principle:%20Managing%20drug%E2%80%93drug%20interactions%20when%20the%20risks%20are%20unclear&rft.jtitle=JAACP%20:%20Journal%20of%20the%20American%20College%20of%20Clinical%20Pharmacy&rft.au=Hansten,%20Philip%20D.&rft.date=2024-12&rft.volume=7&rft.issue=12&rft.spage=1197&rft.epage=1206&rft.pages=1197-1206&rft.issn=2574-9870&rft.eissn=2574-9870&rft_id=info:doi/10.1002/jac5.2031&rft_dat=%3Cwiley_cross%3EJAC52031%3C/wiley_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true